Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMSBusiness Wire • 04/21/26
Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGADGlobeNewsWire • 04/21/26
Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGADBusiness Wire • 04/21/26
FDA accepts application for Roche's Gazyva/Gazyvaro for the treatment of the most common form of lupusGlobeNewsWire • 04/21/26
FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of LupusBusiness Wire • 04/21/26
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosisGlobeNewsWire • 04/13/26
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billionReuters • 04/09/26
Trump threatens 100% tariff on US drug makers that don't strike deals to lower pricesThe Guardian • 04/02/26
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supplyGlobeNewsWire • 03/30/26
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE marketsPRNewsWire • 03/24/26
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and developmentGlobeNewsWire • 03/23/26
Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both)Seeking Alpha • 03/18/26
Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designationPRNewsWire • 03/18/26